FOLH1 and metastatic prostate carcinoma: Castrate‐resistant patients were not included in this study but further exploration in this setting is certainly warranted and is currently being investigated through the STAMPEDE2 trial of SBRT compared with Lu‐PSMA‐617 treatment in metastatic prostate cancer.22